FDA Grants Orphan Drug Designation for TRM-201 (rofecoxib) for the Treatment of Hemophilic Arthropathy
CAMBRIDGE, Mass.--(BUSINESS WIRE) November 21, 2017 --Tremeau Pharmaceuticals, Inc., a new pharmaceutical company focused on providing non-opioid pain treatments for rare diseases, announced today that the U.S. Food and Drug Administration (FDA) has...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials
More News: Clinical Trials | Food and Drug Administration (FDA) | Grants | Pain | Pharmaceuticals | Rare Diseases | Vioxx